Literature DB >> 17511675

CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects.

S M Kang1, Q Tang, J A Bluestone.   

Abstract

The involvement of CD4(+)CD25(+) regulatory T cells (Treg) in general immune homeostasis and protection from autoimmune syndromes is now well established. Similarly, there has been increasing evidence for Treg involvement in allograft rejection and current immunotherapies. However, despite significant advances in understanding the development, function, and therapeutic efficacy of Treg in certain well-defined rodent models, the relevance of Treg to clinical transplantation remains unclear. In this review, we summarize our current understanding of the role of Treg in immunity and organ transplantation in experimental and clinical settings. In addition, we review advances in using Treg as a form of immune therapy. The goal is to highlight the complexities and opportunities in the field and to provide evidence to support the use of antigen-specific Tregs in the context of transplantation to facilitate a robust and selective state of immune tolerance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17511675     DOI: 10.1111/j.1600-6143.2007.01829.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  57 in total

1.  Selective resistance of CD44hi T cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation.

Authors:  Zhenyu Yao; Jennifer Jones; Holbrook Kohrt; Samuel Strober
Journal:  J Immunol       Date:  2011-09-19       Impact factor: 5.422

2.  Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants.

Authors:  David Hongo; Xiaobin Tang; Suparna Dutt; Roland G Nador; Samuel Strober
Journal:  Blood       Date:  2011-12-15       Impact factor: 22.113

Review 3.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

4.  Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs.

Authors:  Shipra Gupta; Thomas B Thornley; Wenda Gao; Rafael Larocca; Laurence A Turka; Vijay K Kuchroo; Terry B Strom
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

Review 5.  The biology of FoxP3: a key player in immune suppression during infections, autoimmune diseases and cancer.

Authors:  Frances Mercer; Derya Unutmaz
Journal:  Adv Exp Med Biol       Date:  2009       Impact factor: 2.622

Review 6.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

Review 7.  Mechanisms of self-nonself discrimination and possible clinical relevance.

Authors:  Carolin Daniel; Jens Nolting; Harald von Boehmer
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

8.  Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo.

Authors:  N M Rogers; S Kireta; P T H Coates
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

9.  Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients.

Authors:  Giorgio Raimondi; Tina L Sumpter; Benjamin M Matta; Mahesh Pillai; Natasha Corbitt; Yoram Vodovotz; Zhiliang Wang; Angus W Thomson
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

10.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

Authors:  Dat Q Tran; John Andersson; Donna Hardwick; Lolita Bebris; Gabor G Illei; Ethan M Shevach
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.